Is MultiValent Biotherapies, Inc. a real, registered company?
MultiValent Biotherapies, Inc. is a registered filer with the SEC (CIK 2107846) and has filed since 2026-02-27. 2 filings are on record, the latest on 2026-03-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has MultiValent Biotherapies, Inc. raised?
Its new offerings report $10.02M sold across 2 offerings, as its own filings state.
Run the free check on MultiValent Biotherapies, Inc. →
LOS ALTOS, CALIFORNIA
2025
Biotechnology
2
$10.02M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-03-02 | New offering first sale 2026-01-09 | $10.01M | — | details · SEC filing |
| 2026-02-27 | New offering first sale 2026-01-05 | $4K | $4K | SEC filing |
Keep reading
More on MultiValent Biotherapies, Inc. and the records around it.
MultiValent Biotherapies, Inc. elsewhere on the record
- Form D filing Mar 2026
Watch MultiValent Biotherapies, Inc.
Get an email when MultiValent Biotherapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with MultiValent Biotherapies, Inc.?
Who to contact
- Fred Schwarzer — Executive Officer, Director, Promoter
- Stephen Snowdy — Executive Officer, Director, Promoter
- Bruce Keyt — Executive Officer, Director, Promoter
- Deborah Schwarzer — Executive Officer, Director, Promoter
- Round: Form D filed 2026-03-02
- Amount sold: $10.01M
- Industry: Biotechnology
- Founded: 2025
- Based: LOS ALTOS, CALIFORNIA
People listed
- Fred Schwarzer — Executive Officer, Director, Promoter
- Stephen Snowdy — Executive Officer, Director, Promoter
- Bruce Keyt — Executive Officer, Director, Promoter
- Deborah Schwarzer — Executive Officer, Director, Promoter
- Filing: Form D filed 2026-03-02
- Amount sold: $10.01M
- Industry group: Biotechnology
- Year formed: 2025
- Based: LOS ALTOS, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when MultiValent Biotherapies, Inc. raises, hires or launches. No email unless you switch it on.
Watch MultiValent Biotherapies, Inc. →Want the whole picture on MultiValent Biotherapies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on MultiValent Biotherapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MultiValent Biotherapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from MultiValent Biotherapies, Inc.'s own filings with the SEC. The people those filings name are on the team page.